Skip to main content
. 2020 Dec 7;11:606497. doi: 10.3389/fphar.2020.606497

FIGURE 2.

FIGURE 2

(A) BASFI, (B) BASMIlin, and (C) chest expansion at each time point during the 24-week treatment period in patients treated with HS016 or adalimumab. *p < 0.05, compared with baseline in the HS016 group; # p < 0.05, compared with baseline in the adalimumab group. BASFI, Bath ankylosing spondylitis functional index; BASMIlin, linear Bath ankylosing spondylitis metrology index.